Figure 3
From: Improving physical activity in COPD: towards a new paradigm
Change in morning activities (absolute scores) over treatment period with budesonide/formoterol plus tiotropium versus placebo plus tiotropium [74]. CDLM: Capacity of Daily Living during the Morning questionnaire; dotted line represents budesonide/formoterol plus tiotropium; solid line represents placebo plus tiotropium; CDLM score at run-in budesonide/formoterol plus tiotropium: 4.09, placebo plus tiotropium: 4.13; †treatment comparison from randomization to first week of treatment; ‡treatment comparison from randomization to last week of treatment. Reprinted with permission of the American Thoracic Society. Copyright © 2013 American Thoracic Society. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741–750. Official journal of the American Thoracic Society.